PCSK9 and familial isolated congenital asplenia: The findings of a multicenter prospective cohort study demonstrate that patients with ICAS who received PCSK9 inhibitors in addition to statin therapy showed lowered LDL-C levels and exhibited a reduced incidence rate of early recurrent stroke [27], highlighting the potential benefits of this combination treatment.